血小板反应蛋白2与肿瘤

doi:10.3760/cma.j.cn371439-20200401-00032

国际肿瘤学杂志 ›› 2021, Vol. 48 ›› Issue (3): 164-166.doi: 10.3760/cma.j.cn371439-20200401-00032

血小板反应蛋白2与肿瘤

范冲冲, 乔建瓯^*()

上海交通大学医学院附属第九人民医院呼吸内科 200001

收稿日期:2020-04-01 修回日期:2020-11-15 出版日期:2021-03-08 发布日期:2021-03-25
通讯作者: 乔建瓯 E-mail:qjou@163.com
基金资助:
国家自然科学基金(81170028)

Thrombospondin 2 and tumors

Fan Chongchong, Qiao Jian'ou^*()

Department of Respiratory Medicine, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200001, China

Received:2020-04-01 Revised:2020-11-15 Online:2021-03-08 Published:2021-03-25
Contact: Qiao Jian'ou E-mail:qjou@163.com
Supported by:
National Natural Science Foundation of China(81170028)

摘要/Abstract

摘要：

血小板反应蛋白(THBS)2作为THBS家族的一员,在多种肿瘤细胞中表达,且在肿瘤的发展及转移中具有重要意义。近年来,研究报道THBS2在不同肿瘤中的具体作用不同,并参与多种生物学过程,如细胞凋亡、伤口愈合、血管生成和炎症反应。目前THBS2在肿瘤发生发展及预后中的作用尚未完全明确,探讨THBS2在肿瘤中的异常表达及作用机制有望为肿瘤的诊断和治疗提供新的方法。

关键词: 肿瘤, 血小板反应蛋白2

Abstract:

Thrombospondin (THBS) 2, as a member of the THBS family, is expressed in a variety of tumor cells and has important significance in the development and metastasis of tumors. In recent years, studies have reported that the specific role of THBS2 in different tumors is different, and it participates in a variety of biological processes, such as cell apoptosis, wound healing, angiogenesis and inflammation. At present, the role of THBS2 in tumorigenesis, development, and prognosis is not completely clear. Exploring the abnormal expression and mechanism of THBS2 in tumors is expected to provide a new method for tumor diagnosis and treatment.

Key words: Neoplasms, Thrombospondin 2

范冲冲, 乔建瓯. 血小板反应蛋白2与肿瘤[J]. 国际肿瘤学杂志, 2021, 48(3): 164-166.

Fan Chongchong, Qiao Jian'ou. Thrombospondin 2 and tumors[J]. Journal of International Oncology, 2021, 48(3): 164-166.

参考文献 25

[1]	Weng TY, Wang CY, Hung YH, et al. Differential Expression pattern of THBS1 and THBS2 in lung cancer: clinical outcome and a systematic-analysis of microarray databases[J]. PLoS One, 2016,11(8):e0161007. DOI: 10.1371/journal.pone.0161007. doi: 10.1371/journal.pone.0161007 pmid: 27513329
[2]	Kim J, Bamlet WR, Oberg AL, et al. Detection of early pancreatic ductal adenocarcinoma with thrombospondin-2 and CA19-9 blood markers[J]. Science Translational Medicine, 2017,9(398):eaah5583. DOI: 10.1126/scitranslmed.aah5583.
[3]	Wang X, Zhang L, Li H, et al. THBS2 is a potential prognostic biomarker in colorectal cancer[J]. Sci Rep, 2016,6:33366. DOI: 10.1038/srep33366.
[4]	Sun R, Wu J, Chen Y, et al. Down regulation of thrombospondin2 predicts poor prognosis in patients with gastric cancer[J]. Mol Cancer, 2014,13:225. DOI: 10.1186/1476-4598-13-225. doi: 10.1186/1476-4598-13-225 pmid: 25262009
[5]	吴湘光, 魏文斐, 梁莉, 等. THBS2在宫颈癌中的表达及功能研究[J]. 现代妇产科进展, 2017,26(12):889-892. DOI: 10.13283/j.cnki.xdfckjz.2017.12.002.
[6]	Koch M, Hussein F, Woeste A, et al. CD36-mediated activation of endothelial cell apoptosis by an N-terminal recombinant fragment of thrombospondin-2 inhibits breast cancer growth and metastasis in vivo[J]. Breast Cancer Res Treat, 2011,128:337-346. DOI: 10.1007/s10549-010-1085-7. doi: 10.1007/s10549-010-1085-7 pmid: 20714802
[7]	Carlson CB, Lawler J, Mosher DF. Structures of thrombospondins[J]. Cell Mol Life Sci, 2008,65(5):672-686. DOI: 10.1007/s00018-007-7484-1. pmid: 18193164
[8]	Mirochnik Y, Kwiatek A, Volpert OV. Thrombospondin and apoptosis: molecular mechanisms and use for design of complementation treatments[J]. Curr Drug Targets, 2008,9(10):851-862. DOI: 10.2174/138945008785909347.
[9]	Calabro NE, Kristofik NJ, Kyriakides TR. Thrombospondin-2 and extracellular matrix assembly[J]. Biochim Biophys Acta, 2014,1840(8):2396-2402. DOI: 10.1016/j.bbagen.2014.01.013.
[10]	Bornstein P. Thrombospondins as matricellular modulators of cell function[J]. J Clin Invest, 2001,107(8):929-934. DOI: 10.1172/JCI12749.
[11]	Liu JF, Lee CW, Tsai MH, et al. Thrombospondin 2 promotes tumor metastasis by inducing matrix metalloproteinase-13 production in lung cancer cells[J]. Biochem Pharmacol, 2018,155:537-546. DOI: 10.1016/j.bcp.2018.07.024. doi: 10.1016/j.bcp.2018.07.024 pmid: 30031810
[12]	Del Pozo Martin Y, Park D, Ramachandran A, et al. Mesenchymal cancer cell-stroma crosstalk promotes niche activation, epithelial reversion, and metastatic colonization[J]. Cell Rep, 2015,13(11):2456-2469. DOI: 10.1016/j.celrep.2015.11.025. pmid: 26670048
[13]	杨柳, 罗黔. 胰腺癌组织高表达血小板反应蛋白2的预后意义及其对癌细胞增殖和迁移的影响[J]. 中国肿瘤生物治疗杂志, 2019,26(2):206-212. DOI: 10.3872/j.issn.1007-385x.2019.02.011.
[14]	Peng HY, Chang MC, Hu CM, et al. Thrombospondin-2 is a highly specific diagnostic marker and is associated with prognosis in pancreatic cancer[J]. Ann Surg Oncol, 2019,26(3):807-814. DOI: 10.1245/s10434-018-07109-6. doi: 10.1245/s10434-018-07109-6 pmid: 30569296
[15]	蒋炳林, 何永亮, 陈开蓉. MMP3、THBS2、COL10A1和miR-1229对早期结直肠癌的诊断价值[J]. 标记免疫分析与临床, 2019,26(6):994-999. DOI: 10.11748/bjmy.issn.1006-1703.2019.06.024.
[16]	贺春兰, 张梦兰, 杨勇, 等. 血小板反应素蛋白2在高原地区胃黏膜炎性病变及胃癌患者中表达的差异研究[J]. 中国全科医学, 2016,19(26):3185-3190. DOI: 10.3969/j.issn.1007-9572.2016.26.012.
[17]	Wei WF, Zhou CF, Wu XG, et al. MicroRNA-221-3p, a TWIST2 target, promotes cervical cancer metastasis by directly targeting THBS2[J]. Cell Death Dis, 2017,8(12):3220. DOI: 10.1038/s41419-017-0077-5.
[18]	Calabro NE, Barrett A, Chamorro-Jorganes A, et al. Thrombospondin-2 regulates extracellular matrix production, LOX levels, and cross-linking via downregulation of miR-29[J]. Matrix Biol, 2019,82:71-85. DOI: 10.1016/j.matbio.2019.03.002.
[19]	董婷婷, 戴盛康, 龙颖, 等. 过表达THBS2对宫颈鳞癌SiHa细胞生物学特性的影响[J]. 中国癌症防治杂志, 2018,10(6):427-433. DOI: 10.3969/j.issn.1674-5671.2018.06.02.
[20]	Bertin N, Clezardin P, Kubiak R, et al. Thrombospondin-1 and -2 messenger RNA expression in normal, benign, and neoplastic human breast tissues: correlation with prognostic factors, tumor angiogenesis, and fibroblastic desmoplasia[J]. Cancer Res, 1997,57(3):396-399. pmid: 9012463
[21]	莫超华. 基于芯片、测序数据及CMAP方法对乳腺癌差异表达基因的研究[D]. 南宁: 广西医科大学, 2018.
[22]	Hsu CW, Yu JS, Peng PH, et al. Secretome profiling of primary cells reveals that THBS2 is a salivary biomarker of oral cavity squamous cell carcinoma[J]. J Proteome Res, 2014,13(11):4796-4807. DOI: 10.1021/pr500038k. doi: 10.1021/pr500038k
[23]	Chang IW, Li CF, Lin VC, et al. Prognostic impact of thrombospo-din-2 (THBS2) overexpression on patients with urothelial carcinomas of upper urinary tracts and bladders[J]. J Cancer, 2016,7(11):1541-1549. DOI: 10.7150/jca.15696. doi: 10.7150/jca.15696 pmid: 27471570
[24]	Slavin S, Yeh CR, Da J, et al. Estrogen receptor α in cancer-associated fibroblasts suppresses prostate cancer invasion via modulation of thrombospondin 2 and matrix metalloproteinase 3[J]. Carcinogenesis, 2014,35(6):1301-1309. DOI: 10.1093/carcin/bgt488. pmid: 24374826
[25]	Zhang J, Hao N, Liu W, et al. In-depth proteomic analysis of tissue interstitial fluid for hepatocellular carcinoma serum biomarker discovery[J]. Br J Cancer, 2017,117(11):1676-1684. DOI: 10.1038/bjc.2017.344. pmid: 29024941

血小板反应蛋白2与肿瘤

Thrombospondin 2 and tumors

RichHTML

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献 25

相关文章 15

编辑推荐

Metrics

本文评价

[1]	刘娜, 寇介丽, 杨枫, 刘桃桃, 李丹萍, 韩君蕊, 杨立洲. 血清miR-106b-5p、miR-760联合低剂量螺旋CT诊断早期肺癌的临床价值[J]. 国际肿瘤学杂志, 2024, 51(6): 321-325.
[2]	杨蜜, 别俊, 张加勇, 邓佳秀, 唐组阁, 卢俊. 局部晚期可切除食管癌新辅助治疗疗效及预后分析[J]. 国际肿瘤学杂志, 2024, 51(6): 332-337.
[3]	袁健, 黄燕华. Hp-IgG抗体联合血清DKK1、sB7-H3对早期胃癌的诊断价值[J]. 国际肿瘤学杂志, 2024, 51(6): 338-343.
[4]	陈红健, 张素青. 血清miR-24-3p、H2AFX与肝癌患者临床病理特征及术后复发的关系研究[J]. 国际肿瘤学杂志, 2024, 51(6): 344-349.
[5]	郭泽浩, 张俊旺. PFDN及其亚基在肿瘤发生发展中的作用[J]. 国际肿瘤学杂志, 2024, 51(6): 350-353.
[6]	张百红, 岳红云. 新作用机制的抗肿瘤药物进展[J]. 国际肿瘤学杂志, 2024, 51(6): 354-358.
[7]	许凤琳, 吴刚. EBV在鼻咽癌肿瘤免疫微环境和免疫治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 359-363.
[8]	王盈, 刘楠, 郭兵. 抗体药物偶联物在转移性乳腺癌治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 364-369.
[9]	张蕊, 褚衍六. 基于FIT与肠道菌群的结直肠癌风险评估模型的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 370-375.
[10]	高凡, 王萍, 杜超, 褚衍六. 肠道菌群与结直肠癌非手术治疗的相关研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 376-381.
[11]	王丽, 刘志华, 杨伟洪, 蒋凤莲, 李全泳, 宋浩杰, 鞠文东. ROS1突变肺腺鳞癌合并脑梗死为主要表现的Trousseau综合征1例[J]. 国际肿瘤学杂志, 2024, 51(6): 382-384.
[12]	刘静, 刘芹, 黄梅. 基于SMOTE算法的食管癌放化疗患者肺部感染的预后模型构建[J]. 国际肿瘤学杂志, 2024, 51(5): 267-273.
[13]	杨琳, 路宁, 温华, 张明鑫, 朱琳. 炎症负荷指数与胃癌临床关系研究[J]. 国际肿瘤学杂志, 2024, 51(5): 274-279.
[14]	王俊毅, 洪楷彬, 纪荣佳, 陈大朝. 癌结节对结直肠癌根治性切除术后肝转移的影响[J]. 国际肿瘤学杂志, 2024, 51(5): 280-285.
[15]	张宁宁, 杨哲, 檀丽梅, 李振宁, 王迪, 魏永志. 宫颈细胞DNA倍体分析联合B7-H4和PKCδ对宫颈癌的诊断价值[J]. 国际肿瘤学杂志, 2024, 51(5): 286-291.